Dr Gepke Delwel,
Senior Policy Advisor
College voor Zorgverzekeringen

Gepke Delwel studied BioMedical Sciences (Faculty of Medicine, State University of Leiden). She holds a PhD for her research on cell adhesion molecules in the Netherlands Cancer Institute (Amsterdam). After her PhD research she got involved in Pharmaco-economics. As a consultant for The Lewin Group she worked on international pharmaco-economic studies and disease management programmes for a number of pharmaceutical companies. In 2000 she joined the Health Care Insurance Board as a policy advisor on pharmaco-economics. She was involved in the implementation of pharmaco-economics in the appraisal procedure for the reimbursement of new drugs. The first experiences with the appraisal of pharmaco-economic studies have been evaluated and the guidelines for pharmaco-economic research, the costing manual and the appraisal procedure were revised. From January 1st 2005 pharmaco-economic studies are obligatory for the reimbursement of new drugs. She is involved in the technical appraisal of these studies. In 2006 the Health Care Insurance Board started with the appraisal of expensive hospital drugs. Part of the appraisal process is outcomes research on clinical, economic and patient reported outcomes of these drugs. Currently, her focus is the implementation and technical requirements of outcomes research in the appraisal process of hospital drugs.

Appearing:

Day One – Wednesday 9 December 2009

3.50pm

HTA in the Netherlands

The role of HTA in coverage decisions: assessment and appraisal in the Netherlands
The role of the cost-effectiveness criterium in the reimbursement of extramural drugs based on an evaluation of submissions from 2005 onwards.
Latest developments on conditional reimbursement 'CED' for hospital based drugs: guidance for outcomes research and the decisions process based on results of outcomes research

Dr Gepke Delwel,

Senior Policy Advisor,
College voor Zorgverzekeringen

back to programme »

view all speakers »

Sponsors

our speakers

Meindert Boysen

Associate Director Single Technology Appraisals

NICE

Dr François Meyer

Director, Health Technology Assessment Division

Haute Autorité de

Santé

Dr Allan Korn

Senior Vice President, Chief Medical Officer

BlueCross BlueShield Association

Jerome Boehm

Head EU level activities on HTA

European Commission

Dr Matthias Perleth

Head of Methods Department

Gemeinsamer Bundesausschuss

Dr Gepke Delwel,Senior Policy AdvisorCollege voor Zorgverzekeringen

HTA in the Netherlands

Dr Gepke Delwel,
Senior Policy Advisor
College voor Zorgverzekeringen